5 assets in Hepatorenal Syndrome

Therapeutic assets addressing Hepatorenal Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Gly-Gly-Gly-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-Nh2 (4-9 Disulfide) Hepatorenal Syndrome	Noorik Biopharmaceuticals AG	P4	A (84)
Normal Human Serum Albumin Hepatorenal Syndrome	Massachusetts General Hospital	P4	BBB (72)
[Phe^2,Ile^3,Dab(Phac-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-Igln-Lys(Ac)-Epsilon-Lys)^8]Vasopressin Hepatorenal Syndrome	Ocelot Bio, Inc	P2	B (57)
Ambrisentan Hepatorenal Syndrome	Noorik Biopharmaceuticals AG	P2	CC (42)
Noradrenalin Hepatorenal Syndrome	University Hospital Freiburg	P3	NR ()